Braich T A, Salmon S E, Robertone A, Alberts D S, Jones S E, Miller T P, Garewal H S
Invest New Drugs. 1986;4(3):269-74. doi: 10.1007/BF00179595.
A phase II trial of esorubicin (4' deoxydoxorubicin) was performed in patients with cancers of the breast, colon, kidney, lung and melanoma. Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin. No objective responses (complete or partial) were seen in patients with colon cancer (18 patients), lung cancer (12 patients), renal cell cancer (12 patients) and melanoma (18 patients). Myelo-suppression was the most significant toxicity encountered with granulocytopenia (neutrophils less than 1,000) observed in 38% of patients. As discussed, we feel that further investigation of esorubicin in anthracycline-sensitive tumors is warranted.
对患有乳腺癌、结肠癌、肾癌、肺癌和黑色素瘤的患者进行了表柔比星（4' - 脱氧阿霉素）的II期试验。在接受表柔比星治疗的16例乳腺癌患者中观察到2例部分缓解。在结肠癌（18例患者）、肺癌（12例患者）、肾细胞癌（12例患者）和黑色素瘤（18例患者）患者中未观察到客观缓解（完全或部分缓解）。骨髓抑制是最显著的毒性反应，38%的患者出现粒细胞减少（中性粒细胞少于1000）。如前所述，我们认为有必要对表柔比星在蒽环类药物敏感肿瘤中的进一步研究。
